Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 19505918)

1.

A cohort study of p27 localization in colon cancer, body mass index, and patient survival.

Ogino S, Shima K, Nosho K, Irahara N, Baba Y, Wolpin BM, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1849-58. doi: 10.1158/1055-9965.EPI-09-0181.

2.

Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype.

Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, Buchanan DD, Casey G, Cleary SP, Cotterchio M, Farris AB, Figueiredo JC, Gallinger S, Green RC, Haile RW, Hopper JL, Jenkins MA, Le Marchand L, Makar KW, McLaughlin JR, Potter JD, Renehan AG, Sinicrope FA, Thibodeau SN, Ulrich CM, Win AK, Lindor NM, Limburg PJ.

Cancer Epidemiol Biomarkers Prev. 2015 Jun 2. pii: cebp.0094.2015. [Epub ahead of print]

PMID:
26038390
3.

Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.

Felix AS, Sherman ME, Hewitt SM, Gunja MZ, Yang HP, Cora RL, Boudreau V, Ylaya K, Lissowska J, Brinton LA, Wentzensen N.

Front Oncol. 2015 Feb 9;5:25. doi: 10.3389/fonc.2015.00025. eCollection 2015.

4.

Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.

Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu K, Meyerhardt JA, Fuchs CS, Harris CC, Qian ZR, Ogino S.

Ann Surg Oncol. 2015 Apr;22(4):1226-35. doi: 10.1245/s10434-014-4159-7. Epub 2014 Oct 18.

PMID:
25326395
5.

Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis.

Inamura K, Yamauchi M, Nishihara R, Lochhead P, Qian ZR, Kuchiba A, Kim SA, Mima K, Sukawa Y, Jung S, Zhang X, Wu K, Cho E, Chan AT, Meyerhardt JA, Harris CC, Fuchs CS, Ogino S.

J Natl Cancer Inst. 2014 Sep 4;106(9). pii: dju195. doi: 10.1093/jnci/dju195. Print 2014 Sep.

PMID:
25190725
6.

SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.

Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S, Qian ZR.

Ann Surg Oncol. 2014 Dec;21(13):4164-73. doi: 10.1245/s10434-014-3888-y. Epub 2014 Jul 15.

PMID:
25023548
7.

Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.

Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, van Herk-Sukel MP, van Wezel T, Fodde R, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ.

JAMA Intern Med. 2014 May;174(5):732-9. doi: 10.1001/jamainternmed.2014.511.

PMID:
24687028
8.

Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.

Kim JH, Rhee YY, Bae JM, Cho NY, Kang GH.

Am J Surg Pathol. 2013 Oct;37(10):1532-41. doi: 10.1097/PAS.0b013e31829ab1c1.

PMID:
24025523
9.

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.

Bae JM, Kim JH, Cho NY, Kim TY, Kang GH.

Br J Cancer. 2013 Aug 20;109(4):1004-12. doi: 10.1038/bjc.2013.430. Epub 2013 Jul 30.

10.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

11.

PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.

Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Clin Cancer Res. 2013 Jun 15;19(12):3285-96. doi: 10.1158/1078-0432.CCR-12-3614. Epub 2013 Apr 30.

12.

Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.

Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T, Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1142-52. doi: 10.1158/1055-9965.EPI-13-0108. Epub 2013 Apr 29.

13.

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G.

BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36.

14.

Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status.

Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, Liao X, Qian ZR, Ng K, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S.

Cancer Res. 2013 Mar 1;73(5):1600-10. doi: 10.1158/0008-5472.CAN-12-2276. Epub 2013 Feb 26.

15.

Clinical significance of microRNA-93 downregulation in human colon cancer.

Xiao ZG, Deng ZS, Zhang YD, Zhang Y, Huang ZC.

Eur J Gastroenterol Hepatol. 2013 Mar;25(3):296-301. doi: 10.1097/MEG.0b013e32835c077a.

PMID:
23354160
16.

Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.

Wangefjord S, Brändstedt J, Lindquist KE, Nodin B, Jirström K, Eberhard J.

Diagn Pathol. 2013 Jan 21;8:10. doi: 10.1186/1746-1596-8-10.

17.

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.

Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

Cancer. 2013 Apr 15;119(8):1528-36. doi: 10.1002/cncr.27938. Epub 2013 Jan 10.

18.

Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer.

Alipour S, Kennecke HF, Woods R, Lim HJ, Speers C, Brown CJ, Gill S, Renouf DJ, Cheung WY.

J Gastrointest Cancer. 2013 Jun;44(2):203-10. doi: 10.1007/s12029-012-9472-4.

PMID:
23264206
19.

LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Shigaki H, Baba Y, Watanabe M, Murata A, Iwagami S, Miyake K, Ishimoto T, Iwatsuki M, Baba H.

Gastric Cancer. 2013 Oct;16(4):480-7. doi: 10.1007/s10120-012-0209-7. Epub 2012 Nov 21.

20.

Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.

Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E.

J Natl Cancer Inst. 2012 Nov 7;104(21):1635-46. doi: 10.1093/jnci/djs427. Epub 2012 Oct 25. Erratum in: J Natl Cancer Inst. 2013 Jan 16;105(2):151-2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk